BACKGROUND: This study aims to assess the impact of sotatercept on exercise tolerance,
exercise capacity, and right ventricular function in pulmonary arterial hypertension …

Sotatercept is the first successful therapy to make it through phase 3 to regulatory
submission in pulmonary arterial hypertension that is not proposed to work via vasodilatory …

Background Pulmonary arterial hypertension is a progressive disease involving proliferative
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated …

Background Pulmonary arterial hypertension is characterized by pulmonary vascular
remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone …

Background In participants with pulmonary arterial hypertension, 24 weeks of sotatercept
resulted in a significantly greater reduction from baseline in pulmonary vascular resistance …

Abstract Sotatercept (sotatercept-csrk; WINREVAIRTM) is an activin signalling inhibitor that
is being developed by Merck and Co., Inc.(Rahway, NJ, USA) for the treatment of pulmonary …

Patients with pulmonary arterial hypertension (PAH) who are admitted to the hospital pose a
challenge to the multidisciplinary healthcare team due to the complexity of the …

Figure 1 Traditional and next-generation therapies for PAH. Traditional therapy for PAH is
based on combining two or three vasodilators targeting endothelin 1, NO, and prostacyclin …

Sotatercept is an investigational product that is not approved for any use in any country.
ActRIIA/B: activin receptor type 2A/B; ALK: activin receptor-like kinase; BMP: bone …

Humbert et al.[1] report safety and efficacy results from the long-term open-label extension
study of the phase 2 PULSAR placebo-controlled, randomised trial of sotatercept in …